A detailed history of Trust CO Of Vermont transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Trust CO Of Vermont holds 200 shares of HALO stock, worth $12,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$12,464
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$33.68 - $41.95 $6,736 - $8,390
200 New
200 $8,000
Q2 2022

Jul 20, 2022

BUY
$37.35 - $48.3 $7,470 - $9,660
200 New
200 $9,000
Q1 2022

Apr 05, 2022

SELL
$31.97 - $41.06 $6,394 - $8,212
-200 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$31.82 - $40.75 $6,364 - $8,150
200 New
200 $8,000
Q3 2021

Oct 22, 2021

SELL
$38.47 - $46.42 $7,694 - $9,284
-200 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$16.75 - $20.8 $3,350 - $4,160
200
200 $4,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.68B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Trust CO Of Vermont Portfolio

Follow Trust CO Of Vermont and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trust CO Of Vermont, based on Form 13F filings with the SEC.

News

Stay updated on Trust CO Of Vermont with notifications on news.